Gupta, Kartik

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 4,681

Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk

Bhatia, K., Jain, V., Gupta, K., Bansal, A., Fox, A., Qamar, A., Damman, K., & Vaduganathan, M. (2021) · European Journal of Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 30

Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future

Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 12

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions

Gupta, K., Hirsch, J. R., Kalsi, J., Patel, V., Gad, M. M., & Virani, S. S. (2023) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 9